May
5
2020
On demand

Stable AAV producer cell lines: elevating vector manufacturing

Sponsor
Stable AAV producer cell lines: elevating vector manufacturing

Recombinant adeno-associated virus (rAAV) has shown great promise as a suitable vector for in vivo gene therapies. Consequently, there is a rapidly increasing demand for rAAV production and robust and scalable manufacturing processes.

Currently established rAAV production methods rely on transient transfection of plasmid DNA or transduction of the producing cell with helper viruses.

Using an innovative approach based on its proprietary serum-free suspension cell line, CEVEC has developed a production system that uses rAAV producer cells, which have stably integrated into their genome all the elements required for rAAV assembly as well as the ITR-flanked transgene. For rAAV production, no further transfection steps or helper viruses are required.

The platform can be adapted to various serotypes and transgenes and has been designed for scalable production in stirred tank bioreactors. Data from production runs at different scales will be presented.

Attendees find out how to:

  • Address the production gap for AAV gene therapy vectors
  • Deliver consistent quality across batches of AAV vector through removal of the need for a transfection step
  • Achieve reliable AAV production upon induction of producer cells
  • Optimize scale-up plasmid- and helper virus-free production of AAV vectors in stirred tank bioreactors

Silke Wissing
Silke Wissing
Chief Scientific Officer at CEVEC Pharmaceuticals GmbH

SPEAKERS

Silke Wissing
Silke Wissing
Chief Scientific Officer at CEVEC Pharmaceuticals GmbH

You might also like